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Estrogen receptors α and β 
and aromatase as independent 
predictors for prostate cancer 
outcome
Thea Grindstad1, Kaja Skjefstad1, Sigve Andersen2,3, Nora Ness1, Yngve Nordby2, Samer Al-
Saad1,4, Silje Fismen4, Tom Donnem2,3, Mehrdad Rakaee Khanehkenari1, Lill-Tove Busund1,4, 
Roy M. Bremnes1,2 & Elin Richardsen1,4
Androgens are considered important in normal prostate physiology and prostate cancer (PCa) 
pathogenesis. However, androgen-targeted treatment preventing PCa recurrence is still lacking. 
This indicates additional mediators contributing to cancer development. We sought to determine the 
prognostic significance of estrogen receptors, ERα and -β, and the aromatase enzyme in PCa. Tissue 
microarrays were created from 535 PCa patients treated with radical prostatectomy. Expression of ERα, 
ERβ and aromatase were evaluated using immunohistochemistry. Representative tumor epithelial (TE) 
and tumor stromal (TS) areas were investigated separately. Survival analyses were used to evaluate 
the markers correlation to PCa outcome. In univariate analyses, ERα in TS was associated with delayed 
time to clinical failure (CF) (p = 0.042) and PCa death (p = 0.019), while ERβ was associated with reduced 
time to biochemical failure (BF) (p = 0.002). Aromatase in TS and TE was associated with increased time 
to BF and CF respectively (p = 0.016, p = 0.046). Multivariate analyses supported these observations, 
indicating an independent prognostic impact of all markers. When stratifying the analysis according to 
different surgical centers the results were unchanged. In conclusion, significant prognostic roles of ERα, 
ERβ and aromatase were discovered in the in PCa specimens of our large multicenter cohort.
Prostate cancer (PCa) is continually a challenge as one of the leading causes of cancer-related death amongst 
men1. Androgens are considered as key regulators of physiological processes in the prostate, including pros-
tatic growth, differentiation, development and secretory function, but their role in PCa pathogenesis is not yet 
defined2,3. The response to androgens is mediated thorough the androgen receptor (AR), which is expressed in 
both prostatic epithelial and stromal cells4. This androgen-dependency has been thoroughly investigated and 
formed the basis for androgen deprivation therapy (ADT), which is an essential PCa treatment in metastatic dis-
ease. Innovative approaches in androgen signalling targeting are developing. Oral inhibitors targeting CYP-17 (by 
abiraterone) and the AR (by enzalutamide) has increased survival in metastatic castration-resistant PCa (CRPC) 
in phase III studies5–8. However, recurrence of CRPC still remains a challenge. This indicates a complexity in the 
progression from invasive cancer to castration refractory disease and additional mediators appear to be involved 
in this malignant transformation.
The involvement of androgens in PCa has led to an increased interest in the involvement of other sex steroid 
hormones and their synthesis in PCa development. Local estrogen production happens thorough the conversion 
of androstenedione to estrone, and testosterone to estradiol which is catalyzed by the aromatase enzyme (CYP 
19). This process takes place in several tissues, including the prostate9–11. Aromatase inhibitors are currently 
used in treatment of advanced breast cancer in post-menopausal women. The effect of aromatase inhibitors on 
CRPC has also been investigated, however a beneficial effect has not been shown12,13. So far, results regarding 
local aromatases activity in PCa have been diverging9–11, and few studies have focused on the association between 
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local aromatase expression and PCa. Currently, genetic polymorphism of the aromatase gene, CYP19A1, and it’s 
association to PCa has received interest and is undergoing investigation14–16.
The involvement of estrogens in PCa is not a novel concept2,3. Estrogens were used as the main PCa treatment 
until the 1950s due to their ability to suppress serum testosterone levels via negative feedback on luteinizing hor-
mone (LH) production17. However, as serious cardiovascular side effects were an increasing concern, new ADT 
methods developed (e.g. LH - releasing hormone antagonists) and estrogen treatment was discarded17.
The effects of estrogens are mediated through two different receptors, ERα and ERβ 18, both expressed in the 
human prostate. Estrogens involvement in PCa development received renewed interest after the discovery of the 
second ER receptor (ERβ ) in the prostate18. This has led to development of a paradigm regarding the different 
roles of the ERs in PCa. So far the hypothesis has been that ERβ has a predominantly protective effect in PCa, 
while ERα is oncogenic19–23. However, the role of ERs in PCa remains controversial as opposing results regarding 
their behavior in PCa development are still emerging24–31.
In order to understand the ERs involvement in PCa we have investigated the epithelial and stromal expression 
of ERα , ERβ and aromatase in different tissue compartments in a large cohort of 535 prostatectomy specimens. 
We further analyzed their prognostic impact on patient outcome and correlation to clinicopathological variables. 
All three markers were detected in either tumor related stromal cells (TS), tumor epithelial cells (TE) or both and 
correlated to PCa outcome.
Materials and Methods
Patients and tissue data. Primary tumor tissue from 535 radical prostatectomy (RP) patients was included 
in this study. The tumor tissue was retrospectively collected from the Departments of Pathology at the University 
Hospital of Northern Norway (n = 248), Nordland Hospital (n = 59) and St. Olavs Hospital (n = 228) from the 
period 1995–2005. Patients who had (I) radiotherapy to the pelvic region prior to surgery, (II) other malignan-
cies within 5 years prior to the PCa diagnosis, (III) inadequate paraffin-embedded tissue blocks, and (IV) lack of 
clinical follow-up data, (V) received hormonal therapy prior to or at the time of the prostatectomy, were excluded. 
All primary cancers were histologically reviewed by two pathologists (ER and LTB) and the tumors were graded 
according to the modified Gleason grading system32,33 and staged according to the WHO guidelines34. Median 
follow-up time of survivors was 89 (range 6–188) months at the last patient update in November 2012. The cohort 
is thoroughly described in a previous paper35.
The Regional Committee for Medical and Health Research Ethics (2009/1393), the Data Protection Official for 
Research (NSD), and the National Data Inspection Board approved this study. All patients were made anonymous 
with each trial number. These numbers were initially linked to identity for only one purpose prior; to collect clin-
ical information. Written consent from the patients was considered, but as this was a retrospective study where 
most of the material was more than 10 years old and most of the patients deceased, it was considered not needed. 
The aforementioned parties accepted this solution. All data was analyzed anonymously.
Microarray construction. Tissue Microarray (TMA) construction was chosen for high-throughput molec-
ular pathology analysis. For each case, a pathologist (ER) identified and marked two representative areas of tumor 
tissue (epithelial tumor cells), two with tumor stromal tissue, one area with normal epithelial tissue, and one 
area with normal stromal tissue. From each of these areas, cores were sampled from each donor block in order to 
construct TMA blocks.
The TMAs were assembled using a tissue-arraying instrument (Beecher Instruments, Silver Springs, MD, 
USA). We used a 0.6 mm diameter needle to harvest cores from the marked tissue areas from the correspond-
ing formalin-fixed paraffin-embedded (FFPE) tissue blocks. The samples were inserted into an empty recipient 
paraffin block according to a coordinate pattern. To include all core samples, twelve tissue array blocks were con-
structed. Multiple 4 μ m sections were cut with a Micron microtome (HM355S), affixed to glass slides, and sealed 
with paraffin. The detailed methodology has been reported previously36.
Immunohistochemistry (IHC). The following antibodies were used in this study: Rabbit polyclonal ERα 
antibody (SC-543, Santa cruz, 1/100), mouse monoclonal ERβ antibody (clone PPG5/10, MCA1974s, AbD 
Serotec, 1/10), and goat polyclonal aromatase (CYP-19) antibody (SC-14245, Santa cruz, 1/50). The TMA slide 
sections were deparaffinised and rehydrated and antigen retrieval was performed by microwaving (450 W) in 
0.01 M citrate buffer at pH 6.0 for 20 minutes. The sections were cooled to room temperature (RT) and endoge-
nous peroxidase activity was blocked by incubation with a solution of 0.5% hydrogen peroxide for 10 minutes. 
The sections were then incubated in 5% normal serum ABC kit (Vector Laboratories) for 1 h at RT to block non-
specific binding. Subsequently, the sections were incubated overnight at 4 °C with primary antibodies, however 
for goat polyclonal aromatase the incubation time was 45 minutes at RT. After washing, the sections were incu-
bated with the corresponding secondary antibodies for 1 h at RT. The Vectastain ABC kit (Vector Laboratories) 
was used for the avidin-biotin complex method according the manufacturer’s instructions. The sections were 
lightly counterstained with hematoxylin, dehydrated through an ethanol series, cleared in xylene and mounted. 
Two different controls for our staining method were applied. Firstly, control staining of the sections with an 
isotype-matched control antibody without the primary antibody. Secondly, multiple organ tissue microarray as 
positive and negative tissue controls were used to verify the specificity of the staining in every staining procedure. 
The positive tissue controls comprised ovary for ERα , colon adenocarcinoma for ERβ and placenta for aromatase; 
Negative tissue controls were samples of normal pancreas and liver. Details regarding antibody validation are 
presented in supplementary information (S1) and IHC staining of control tissue is depicted in Fig. 1.
Scoring of IHC. The ARIOL imaging system (Applied Imaging Corp., San Jose, CA, USA) was used to 
scan and digitalize the IHC stained TMA slides. The slides were loaded in the SL 50 automated slide loader and 
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scanned at a low resolution (1.25x) and high resolution (20x) using an Olympus BX61 microscope with an auto-
mated platform (Prior Scientific, Cambridge, UK). Images of the cores were uploaded into the ARIOL Software. 
All samples were de-identified and scored manually by two experienced parties independent of each other: ERα 
and ERβ by two pathologists (ER and SFI) and aromatase by one pathologist (ER) and one MD student (TG) 
trained by an experienced pathologist. Consequently, all reported marker expressions are based on two separate 
evaluations of the tissue cores. The scoring was done semi-quantitatively and both parties were blinded to any 
pathological or clinical information. In case of discrepancy of more than one, the slides were re-examined. When 
selecting the representative pictures of IHC stained TMA cores depicted in Fig. 1, the TMA slides where evaluated 
by microscope and pictures of the selected cores were taken manually through microscope.
Overall, the percentage of ERα and ERβ positive cells varied between the different cores, there was however 
little variation in staining intensity. ERα and ERβ density was therefor given a score between 0–3, reflecting the 
percentage of positive cells in the examined compartment. The applied scoring system was as follows: 0: 0%, 1: 
≤ 5%, 2: 6–50%, 3: > 50%. For aromatase there was an overall high percentage of positive cells, but variation in 
staining intensity was observed. The degree of aromatase protein expression in cytoplasm was therefore graded 
according to the dominant staining intensity. The scoring was done using the following system: 0 = negative, 
1 = weak, 2 = moderate, 3 = strong. For each case, mean scores were calculated. Further, the scoring values were 
dichotomized as high and low intensity or density of stained cells. Both median, mean and quartile cut off values 
were considered, but the optimal cut off was chosen based on adequate number of patients in each group and sta-
tistical trends. The cut off for ERβ in TS and aromatase in TE was defined as the median (1.5, 1.0) value. For ERα 
and aromatase in TS the cut off was set to the value ≥ 1st quartile (0.75, 0.63). Marker expressions were evaluated 
in all the different PCa compartments: Normal epithelia (NE), normal stroma (NS), hyperplasia (H), TE and TS. 
Further, marker expression in the different compartments and their correlation with biochemical failure (BF), 
clinical failure (CF) and prostate cancer death (PCD) was analyzed.
Statistical methods. All statistical analyses were performed using the statistical package IBM SPSS, version 
21 (SPSS Inc., Chicago, IL, USA). A Wilcoxon signed rank test was used to assess differences in ERβ , ERα and 
aromatase expression between the different compartments: TE vs. TS. Spearman correlation coefficient was per-
formed to examine the association between ERβ , ERα , aromatase expression and clinicopathological variables. 
The Kaplan-Meier method was used for the univariate survival analysis, and log-rank test was used to assess 
Figure 1. Immunohistochemical analysis of estrogen receptor (ER)α, ERβ and aromatase in prostate 
cancer (PCa) specimens and tissue controls. Microscopic pictures of tissue micro array representing 
expression of aromatase, estrogen receptor (ER)α and ERβ by immunohistochemistry staining in PCa sections. 
Original magnification x40 showing low and high expression of ERα , ERβ and aromatase in in tumor cells (TE) 
and tumor associated stromal cells (TS) of PCa in addition to positive tissue controls (Pos.TC) and negative 
tissue controls (Neg.TC) for each antibody. Positive tissue controls; ERα – ovary, ERβ –colon adenocarcinoma 
and aromatase – placenta. Negative tissue controls; ERα – liver, ERβ and aromatase – pancreas.
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statistical significance. Univariate analyses were constructed for the following end-points: (1) Biochemical failure 
free survival (BFFS), (2) Clinical failure free survival (CFFS) and (3) PCa death free survival (PCDFS). BF was 
determined as PSA recurrence ≥ 0.4 ng/ml in a minimum of two different blood samples postoperatively37. CF 
was defined as verified local symptomatic recurrence and/or findings of metastasis to bone, visceral organs or 
lymph nodes by CT, MR, bone scan or ultrasonography. PCD was defined as death caused by progressive and dis-
seminated castration-resistant PCa uncontrollable by therapy. All significant variables from the univariate analy-
sis were entered in the multivariate analysis using backward stepwise Cox regression model with a probability for 
stepwise entry removal at 0.05 and 0.1, respectively. The IHC scoring values from each pathologist were compared 
for inter-observer reliability by use of a two-way random effect model with absolute agreement definition. The 
significance level used was p < 0.05 for all analyses.
Results
Patient characteristics. An overview of the patient’s demographic, clinical and histopathological char-
acteristics is presented in Table 1. Median age at surgery was 62 years (47 to 76). The radical prostatectomy was 
retropubic in 435 cases (81%) and perineal in 100 cases (19%). Combined Gleason score ranged from 6-to10 and 
tumor stage from T2a to T3b. Median PSA was 8.8 (range 0.7–104). At the last follow-up in 2012, 170 (32%) had 
experienced BF, 36 (7%) experienced CF and 15 (3%) had died due to PCa.
Scoring agreement. There was a good scoring agreement between the scorers. The intra-class correlation 
coefficient (reliability coefficient, r) was 0.93 (p < 0.001) for the ERα marker and 0.79 (p < 0.001) for the ERβ 
marker and 0.89 (p < 0.001) for the aromatase marker respectively.
Expression of ERα, ERβ and aromatase expression and their correlation with clinicopatholog-
ical variables. ERα and aromatase staining was predominantly cytoplasmic (Fig. 1). The staining of ERβ was 
both nuclear and cytoplasmic (Fig. 1). ERα staining in epithelial cells was primarily negative (NE and TE negative 
in 70 and 64%, respectively) (Fig. 1). For the small selection of patients with a positive epithelial ERα expression, 
no significant difference in BFFS, CFFS or PCDFS was found. ERβ staining was overall positive in stromal and 
epithelial cells of both benign and malignant prostate tissue. The percentage of ERβ positive cells was however 
significantly higher in TE compared to TS (mean value 1.93 and. 1.26 respectively, p < 0.001). Aromatase staining 
was also in general positive. Though, a stronger aromatase expression was detected in NS compared to TS (mean 
value 1.29 and 1.09 respectively, p < 0.001). There was also a stronger aromatase staining intensity in NS com-
pared to NE (mean value 1.29 and 1.05 respectively, p < 0.001). No further difference in expression was detected 
for either marker.
The correlation between marker expressions and clinicopathological variables was weak or non-significant 
(r < 0.2). However, a positive correlation was detected between ERα and ERβ in TS (r = 0.50, p < 0.001). As 
expected, in TS both ERα and ERβ displayed a correlation to aromatase (r = 0.36, p < 0.001 and r = 0.53, 
p < 0.001). The same correlation was observed in TE for ERα , ERβ and aromatase respectively (r = 0.22, 
p < 0.001/r = 0.43, p < 0.001).
Univariate analysis. Variables significant for BF were pT-stage (p < 0.001), pN-stage (< 0.001), preopera-
tive PSA (p < 0.001), Gleason score (p < 0.001), tumor size (p < 0.001), perineural infiltration (PNI, p < 0.001), 
positive surgical margin (PSM, p = 0.041), apical PSM (p = 0.040), non-apical PSM (p < 0.001), and lympho-
vascular infiltration (LVI, p < 0.001). For CF, significant prognostic factors were: pT-stage (p < 0.001), pN-stage 
(p < 0.001), Gleason score (p < 0.001), tumor size (p = 0.019), PNI (p = 0.001), PSM (p = 0.038), non-apical PSM 
(p < 0.001) and LVI (p < 0.001). For PCD the prognostic factors were: pT-stage (p = 0.027), pN-stage (p < 0.001), 
Gleason score (p < 0.001), PNI (p = 0.002), non-apical PSM (p = 0.029) and LVI (p = 0.009).
Results from univariate analysis of molecular markers according to BFFS, CFFS and PCDFS are presented 
in Table 2 and Fig. 2A–F. In TS, a high density of ERα was associated with increased CFFS (p = 0.042) (Fig. 2A) 
and increased PCDFS (p = 0.019) (Fig. 2B), albeit this trend was not displayed in BFFS (p = 0.819). High ERβ 
expression was on the other hand associated with reduced BFFS (p = 0.002) (Fig. 2C). Further, a strong TS stain-
ing intensity of aromatase was associated with increased BFFS (p = 0.016) (Fig. 2D). In TE, a strong intensity 
of aromatase was also associated with increased CFFS (p = 0.036) (Fig. 2E) and similar curves tending towards 
significance were observed for PCDFS (p = 0.061) (Fig. 2F). When stratifying these analyses according to the 
different surgical centers the same trends were displayed. In addition to these findings, we demonstrate a trend 
for the markers ERα in TS and aromatase in TE in adding prognostic value (4–12% reduced 10-year CFFS in low 
versus high expression subgroups) within each pathological PCa stage (Table 3).
When merging the expression levels of ERα and aromatase in TS, a combined high level of the two markers 
(high/high vs. high/low, low/high, low/low) was associated with increased CFFS (p = 0.029) (S1 Table 2). The same 
tendency was also displayed when merging ERα in TS and aromatase in TE. A combined high level (high/high, 
high/low, low/high vs. low/low) was associated with increased CFFS (p = 0.038) and PCDFS (0.003), but not BFFS 
(p = 0.854) (S1 Table 2). Further, when merging the stromal expression of ERβ and aromatase, a beneficial effect 
of a combined level low ERβ and high aromatase (low/high) in BFFS stood out compared to the high ERβ and 
low aromatase (high/low) combination which was associated with reduced time to BFFS (p < 0.001) (S1 Table 2). 
When combining ERβ in TS and aromatase in TE, no obvious trends or significant results were displayed.
Multivariate analysis. Results from multivariate analysis are presented in Table 4. In addition to pT-stage, 
Gleason score ≥ 9 apical PSM, and non-apical PSM, both ERβ (HR: 1.70, 95% CI: 1.19–2.42, p = 0.004) and aro-
matase (HR: 0.55, 95% CI: 0.38–0.80, p = 0.002) in TS were independent prognostic factors for BF. ERα in TS 
emerged as a significant, independent marker for CF (HR: 0.43, 95% CI: 0.22–0.86, p = 0.018) in addition to 
non-apical PSM, PNI and Gleason grade ≥ 9. This was also the case for aromatase in TE (HR: 0.43, 95% CI: 
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0.21–0.90, p = 0.024). Further, ERα in TS was the only marker that served as an independent prognostic factor 
for PCD (HR: 0.28, 95% CI: 0.1–0.78, p = 0.015) along with Gleason grade ≥ 9 and PNI, although aromatase in 
TE tended towards significance. Further, ERα in TS and aromatase in TE combined emerged as an independ-
ent prognostic factor for CF (HR: 0.43, 95% CI: 0.21– 0.87, p = 0.02) and PCD (HR: 0.24, 95% CI: 0.085–0.65, 
p = 0.005). The combination ERα and aromatase and ERβ and aromatase respectively in TS did not reach statis-
tical significance in multivariate analyzes.
Characteristic Patients (n) Patients (%)
BF (170 events) CF (36 events) PCD (15 events)
5-year EFS (%) p 10-year EFS (%) p 10-year EFS (%) p
Age 0.55 0.085 0.600
 ≤ 65 years 357 67 76 92 97
 > 65 years 178 33 70 88 96
pT-Stage <0.001 <0.001 0.027
 pT2 374 70 83 96 98
 pT3a 114 21 60 86 98
 pT3b 47 9 43 73 89
pN-stage <0.001 <0.001 <0.001
 NX 264 49 79 95 98
 N0 268 50 71 89 97
 N1 3 1 0 33 67
Preop PSA <0.001 0.085 0.061
 PSA < 10 308 58 80 93 99
 PSA > 10 221 41 67 88 95
 Missing 6 1 — — —
Gleason <0.001 <0.001 0.001
 3 + 3 183 34 83 98 99
 3 + 4 220 41 76 94 98
 4 + 3 80 15 69 84 95
 4 + 4 19 4 63 76 94
 ≥ 9 33 6 34 67 87
Tumor size <0.001 0.019 0.098
 0–20 mm 250 47 82 94 99
 > 20 mm 285 53 67 88 96
PNI <0.001 <0.001 0.002
 No 401 75 79 95 98
 Yes 134 25 60 81 93
PSM 0.041 0.038 0.697
 No 249 47 81 94 97
 Yes 286 53 69 89 97
Non-apical PSM <0.001 <0.001 0.029
 No 381 71 81 95 98
 Yes 154 29 57 81 94
Apical PSM 0.040 0.484 0.313
 No 325 61 73 90 96
 Yes 210 39 77 92 98
LVI <0.001 <0.001 0.009
 No 492 92 77 93 98
 Yes 43 8 46 71 87
Surgical proc. 0.230 0.414 0.581
 Retropubic 435 81 76 90 97
 Perineal 100 19 67 95 98
Table 1. Patient characteristics and clinicopathological variables as predictors of biochemical failure-
free survival, clinical failure-free survival and disease-specific survival (univariate analysis; log-rank 
test) (N = 535). Abbreviations: BF = biochemical failure; CF = clinical failure; PCD = prostate cancer death; 
PCa = prostate cancer; EFS = event free survival; LVI = lymphovascular infiltration; NR = not reached; 
PNI = Perineural infiltration; Preop = preoperative; PSA = Prostate specific antigen; PSM = Positive surgical 
margin; Surgical proc = surgical procedure.
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Discussion
In our large cohort of 535 PCa specimens, an independent association was detected between PCa outcome and 
ERα , ERβ and aromatase expression. In TS, high-density of ERα was independently and significantly associated 
with both increased CFFS and PCDFS. In contrast, a high ERβ density level was independently and significantly 
associated with reduced BFFS. Further, a strong staining intensity of aromatase in both TS and TE was signifi-
cantly and independently associated with increased BFFS and CFFS respectively. In addition, a correlation and an 
additive effect were discovered when analyzing the combined expression of ERs and aromatase. A major strength 
of our study is the large multicenter cohort and the long follow-up. In addition, our results were validated in two 
different cohorts, yielding data tending towards the end results in the total cohort. In addition, few studies have 
investigated these markers independently in both epithelial and stromal areas of PCa with a clinical event-free 
survival.
In accord with previous publications, ERα density level was predominantly negative in NE in the PCa 
patients23. However, we did not observe an increased expression of epithelial ERα in TE compared to NE, nor 
a previously reported correlation between ERα versus Gleason grade or tumor progression21,28. But notably, 
patients with high ERα level in TS had significantly increased PCDFS. This is supported by other studies24,29–31 
and indicates a more complex role of ERα in PCa than the previously ascribed role as a tumor promoter. In fact, 
Slavin et al. discovered using IHC, in vitro invasion assays and in vivo studies that ERα in TS is beneficial for 
PCa patients29. This could potentially be attributed to a PCa metastasis-suppressing role of ERα 29. In a recent 
follow-up article, Slavin et al.30 further hypothesize that ERα in TS of prostate cancer can be utilized as a prognos-
tic marker to predict cancer progression. In addition, Zellweger et al. detected an improved overall survival for 
CRPC patients with stromal ERα expression24. This is further supported by Celhay et al. who noted survival to be 
significantly reduced in PCa patients with low stromal ERα expression31.
In our material ERβ was expressed, to various extents, in the majority of both epithelial and stromal cells. This 
is in agreement with previous publications23,24,38, although some report ERβ to be predominantly localized in the 
basal cell epithelial compartment and to a lesser extent in the stromal. Many reports, including this, suggest a 
negative role of ERβ expression on PCa prognosis24–28. There have also been reports of a tumor promoting role of 
ERβ , especially in PCa metastasis23,25,26. This may indicate ERβ to exert various effects at different stages of PCa 
development. However, several publications have delivered contradictory reports on the protective role of ERβ in 
PCa, e.g., loss of ERβ as cancer progresses20,22,23. Supporting our findings, Zellweger et al. reported that increased 
ERβ expression in hormone naïve PCa (HNPC) was associated with a worse outcome24. Possible reason for the 
adverse effect of ERβ has previously been described. Yang et al. reported that non-androgenic proliferation of PCa 
can occur through estrogen-mediated activation of AR in complex with ERβ and proline-, glutamic acid- and 
leucine rich protein 1 (PELP1), an AR cofactor known for its proto-oncogenic abilities27. It has also been reported 
a correlation between ERβ and Cyclin D1 in hormone-naïve PCa patients39, a protein with known proliferative 
function.
Recently, several ERβ isoforms have been isolated and different functions of these isoforms have been 
hypothesized, including several with tumor promoting abilities25,26,40. Recent evidence suggests that sub-
type ERβ 2 promotes migration and invasion of cancer cells in addition to cell proliferation, whereas ERβ 1 has 
tumor-suppressing effects26. Further evidence suggest ERβ 2 to be a functional modulator of ERα and ERβ 126. 
Considering the strong correlation between ER subtypes in TS, the hypothesis of an interaction and regulation 
between these receptors is strengthened. Our study and several previous publications, has not investigated ERβ 
isoforms. This is, however, an important topic for future research and could explain some of the previous diverg-
ing results regarding ERβ .
Marker expression Patients (n) Patients (%)
BFFS CFFS PCDFS
5-year (%) 10-year (%) p 5-year (%) 10-year (%) p 5-year (%) 10-year (%) p
ERα TS





0.019High 373 69.7 74 61 97 93 99 98
Missing 18 3.4
ERβ TS





0.486High 149 27.9 67 54 95 91 99 97
Missing 18 3.4
Aromatase TS





0.668High 386 72.1 77 65 97 91 99 98
Missing 18 3.4
Aromatase TE





0.061High 242 45.2 75 64 97 96 99 97
Missing 18 3.4
Table 2. Marker expressions as predictor for BFFS, CFFS and PCDFS in PCa patients (n = 535), (univariate 
analysis; log rank test), significant p-values in bold (threshold p ≤ 0.05). Abbreviations: ERα = estrogen 
receptor alpha; ERβ = estrogen receptor beta; TE = tumor epithelial cells; TS = tumor stromal cells; 
BFFS = Biochemical failure free survival; CFFS = clinical failure free survival; PCDFS = prostate cancer death 
free survival.
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Our study demonstrated a wide distribution of aromatase in stromal and epithelial cells of both benign and 
malignant prostate tissue. Aromatase has previously been detected in both epithelial and stromal tissue, but 
agreement regarding its compartmental expression is however currently lacking9–11. There are limited recent 
studies investigating the expression of aromatase in various prostatic tissue compartments, with respect to PCa 
pathogenesis. However, two studies observed a positive association between aromatase and PCa recurrence31,41, 
contradicting our findings. Genetic polymorphism in the gene encoding aromatase, CYP191A, has also been a 
topic of interest. There have been reports, however with equivocal results, indicating that different single nucleo-
tide polymorphism (SNPs) in CYP191A influences PCa risk and survival14,16. This association is however disputed 
Figure 2. Association with prostate cancer outcome and estrogen receptor (ER) α, ERβ and aromatase 
expression level. Kaplan Meier curves displaying biochemical failure free survival (BFFS), clinical failure free 
survival (CFFS) and prostate cancer death free survival (PCDFS) in relation to high or low expression level of 
ERα , ERβ and aromatase expression in prostate cancer (PCa) patients (n = 535). (A) ERα in tumor associated 
stromal cells (TS) and CFFS. (B) ERα in TS and PCDFS. (C) ERβ in TS and BFFS. (D) Aromatase in TS and 
BFFS. (E) Aromatase in tumor cells (TE) and CFFS. (F) Aromatase in TE and PCDFS.
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by others15. It is not evident how increased aromatization can exert a beneficial mechanism in PCa. Besides the 
role of SNPs and aromatase in PCa, an explanation may be a local depletion of testosterone due to the shuttling of 
testosterone towards estrogen production. This could in turn decrease stimulation of the AR.
By detecting aromatase expression in the PCa specimens, in addition to the strong correlation between aro-
matase and the ERs in TS and TE, we confirm a local production of estrogens in PCa and its stimulation of the 
local receptors. This indicates estrogens’ ability to directly act upon the prostate gland, not only thorough nega-
tive feedback on the hypothalamic-pituitary-gonadal axis. This is of particular interest since it is still unresolved 
whether locally produced or circulating hormones effect PCa more42.
There are several factors that may explain some of the discrepancies regarding these hormonal biomarkers. 
The reproducibility of prognostic biomarker studies is always a challenge43. The cohorts are different, the tissue 
handling and fixation are different, the lab procedures for biomarker detection (in this case IHC) are different and 
details on intraprostatic localization of scoring and the biomarker expression analyses are different. Considering 
the extent of discrepancy in the large number of publications available, a systematic review/meta-analysis 
with subsequent validation of the most promising studies is highly warranted. The heterogenous nature of the 
prostate, the different downstream responses to stimulation of stromal or epithelial receptors, respectively, the 
stromal-epithelial interactions, and the crosstalk between the ARs, ERα s and ERβ s are all factors complicating 
Risk groups of localized 
prostate cancer
10 year CFFS (%)
ERα in TS Aromatase in TE
Low (%) High (%) p Low (%) High (%) p
I (n = 42) NE NE — NE NE —
IIA (n = 109) 92 96 0.886 92 96 0.904
IIB (n = 206) 87 99 0.001 93 97 0.148
III (n = 154) 76 84 0.442 76 88 0.074
Table 3. Ten year CFFS for patients with low or high levels of ERα in TS and aromatase in TE respectively 
in relation to prognostic groups of PCa. The stratification of our cohort into prognostic groups are 
constructed according to the American Joint Committee on Cancer (AJCC) TNM system. By adding either the 
ERα or the aromatase marker to the already well-established clinical markers, prognostic impact is added across 
each pathological stage (univariate analysis; log rank test), significant p-values in bold (threshold p ≤ 0.05). 
Prognostic group IV has been removed due to n = 0. Abbreviations: PCa = prostate cancer; ERα = Estrogen 
receptor α ; TS = tumor associated stroma; TE = Tumor epithelium, CFFS = Clinical failure free survival; 
PSA = Prostate specific antigen; GS = Gleason score; TS = tumor stage; NE = No event.
Marker
BF (n = 170) CF (n = 36) PCD (n = 15)
HR (95% CI) p HR (95% CI) p HR (95% CI) p
pT - stage <0.001
 pT2 1 NE NE
 pT3a 1.81 (1.22–2.63) 0.003
 pT3b 2.84 (1.74–4.65) <0.001
Gleason grade 0.055 0.019 0.085
 3 + 3 1 1 1
 3 + 4 1.02 (0.68–1.51) 0.922 2.12 (0.74–1.20) 0.160 3.55 (0.39–32.03) 0.26
 4 + 3 1.45 (0.90–2.30) 0.127 3.00 (0.94–9.56) 0.063 9.05 (1.02–80.52) 0.048
 4 + 4 1.28 (0.61–2.70) 0.513 2.89 ( 0.55–15.14) 0.210 5.97 (0.36–100.39) 0.22
 ≥ 9 2.27 (1.25–4.12) 0.007 6.80 (2.17–21.32) 0.001 15.67 (1.70–144.62) 0.015
PNI NE 2.12 (1.03–4.39) 0.043 3.4 (1.1–10.53) 0.034
Preop. PSA 1.37 (0.99–1.91) 0.057 NE NE
Apical PSM 0.69 (0.49–0.98) 0.038 NE NE
Non-apical PSM 1.72 (1.21–2.44) 0.002 3.16 (1.52–6.60) 0.002 NE
ERβ TS 1.70 (1.19–2.42) 0.004 NE NE
Aromatase TS 0.55 (0.38–0.80) 0.002 NE NE
Aromatase TE NE 0.43 (0.21–0.90) 0.024 0.33 (0.10–1.04) 0.059
ERα TS NE 0.43 (0.22–0.87) 0.018 0.28 (0.10–0.78) 0.015
Table 4. Cox regression analysis (backwards stepwise model) summarizing significant independent 
prognostic factors for BF, CF and PCD in PCa patients (n = 535), significant p values in bold (0.05 
threshold). Abbreviations: ERα = estrogen receptor alpha; ERβ = estrogen receptor beta; TS = tumor associated 
stromal cells; TE = tumor epithelial cells; BF = biochemical failure; CF = clinical failure; PCD = prostate cancer 
death; PNI = perineural infiltration; PSA = prostate specific antigen; PSM = positive surgical margin; NE = nor 
entered.
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attempts to decipher roles of the different sex steroid hormones in PCa pathogenesis. This complexity is demon-
strated by contradicting results between human PCa samples24,25 and PCa cell line studies11,20,41. As an example, 
several preclinical studies have described protective effects of selective estrogen-receptor modulators (SERM) on 
PCa through the activation of ERβ 44,45. However, this mechanism has to our knowledge never been effectively 
adapted in the clinic. This is also the case for studies investigating ERα blockage and aromatase inhibitors12,13,46.
In the present study, ERs and aromatase emerged as potential prognostic biomarkers for PCa in addition 
to other well-established markers. This is demonstrated by the significant impacts in the multivariate analyses 
(Table 4). In addition, we observed that our markers added prognostic value (4–12% reduced 10-year CFFS in low 
versus high expression subgroups) even within each pathological stage (Table 3). With additional confirmation, 
it is likely that this can be adapted to at least a sub-group of PCa patients in the future.
Conclusion
We found both ERs and aromatase to be significantly and independently associated to PCa outcome. In TS, a high 
expression of ERα was associated with increased CFFS and PCDFS, while a high expression of ERβ was associ-
ated with reduced BFFS. In addition, high aromatase expression in both TS and TE was favorable with respect to 
BFFS and CFFS, respectively. For CFFS, the impact of these markers added prognostic relevance within each stage 
group. This knowledge may be valuable for the development of future prognostic biomarkers in PCa, but further 
validation is warranted before clinical application.
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